{"version":"1.0","provider_name":"Credevo Articles","provider_url":"https:\/\/credevo.com\/articles","author_name":"Trial Expert","author_url":"https:\/\/credevo.com\/articles\/author\/trialexpert\/","title":"Glomerulonephritis - Clinical Trial Feasibility | Credevo Articles","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Zl5xo3Mgmw\"><a href=\"https:\/\/credevo.com\/articles\/2018\/05\/30\/glomerulonephritis-clinical-trial-feasibility\/\">Glomerulonephritis &#8211; Clinical Trial Feasibility<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/credevo.com\/articles\/2018\/05\/30\/glomerulonephritis-clinical-trial-feasibility\/embed\/#?secret=Zl5xo3Mgmw\" width=\"600\" height=\"338\" title=\"&#8220;Glomerulonephritis &#8211; Clinical Trial Feasibility&#8221; &#8212; Credevo Articles\" data-secret=\"Zl5xo3Mgmw\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2018\/11\/Glomerulonephritis_clinical_trial_feasibility_credevo.jpg","thumbnail_width":1280,"thumbnail_height":720,"description":"Glomerulonephritis (GN)&nbsp;is a serious kidney disorder that can lead to end-stage renal disease (ESRD), serious morbidity, or death. Worldwide, IgA Nephropathy (Berger disease) is the most common cause of GN. IgA nephropathy is an autoimmune disease and is one of the most common kidney diseases, other than those caused by diabetes or high blood pressure. [&hellip;]"}